BioHarvest Sciences (NASDAQ:BHST – Get Free Report) and CureVac (NASDAQ:CVAC – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends.
Volatility and Risk
BioHarvest Sciences has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500. Comparatively, CureVac has a beta of 2.53, indicating that its share price is 153% more volatile than the S&P 500.
Profitability
This table compares BioHarvest Sciences and CureVac’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioHarvest Sciences | -76.65% | N/A | -85.16% |
| CureVac | 20.72% | 21.98% | 15.72% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioHarvest Sciences | $22.43 million | 4.80 | -$12.56 million | ($1.25) | -5.24 |
| CureVac | $543.28 million | 1.23 | -$281.58 million | $0.55 | 5.42 |
BioHarvest Sciences has higher earnings, but lower revenue than CureVac. BioHarvest Sciences is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and target prices for BioHarvest Sciences and CureVac, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioHarvest Sciences | 0 | 0 | 2 | 0 | 3.00 |
| CureVac | 0 | 3 | 1 | 0 | 2.25 |
BioHarvest Sciences presently has a consensus price target of $13.00, indicating a potential upside of 98.47%. CureVac has a consensus price target of $10.00, indicating a potential upside of 235.57%. Given CureVac’s higher possible upside, analysts clearly believe CureVac is more favorable than BioHarvest Sciences.
Insider & Institutional Ownership
17.3% of CureVac shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
CureVac beats BioHarvest Sciences on 10 of the 14 factors compared between the two stocks.
About BioHarvest Sciences
BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Receive News & Ratings for BioHarvest Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioHarvest Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
